Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Graphene Could Reshape Neurological Disease Care

By BiotechDaily International staff writers
Posted on 14 May 2014
Image: Structure of graphene (Photo courtesy of Wikimedia).
Image: Structure of graphene (Photo courtesy of Wikimedia).
Graphene, a two-dimensional (2D) crystalline allotrope of carbon, may lead to new advances in several areas of neurosurgery, according to a new topic review.

Researchers at the University of Illinois College of Medicine (Peoria, USA) and Invision Health Brain and Spine Center (Williamsville, NY, USA) argue that neurosurgeons could use graphene-based metamaterials, which possess unique optical, thermal, mechanical, electronic, and quantum properties, to encourage the development of high-performance, lightweight, and malleable electronic devices, ultracapacitors, optical modulators, molecular biodevices, organic photovoltaic cells, lithium-ion microbatteries, frequency multipliers, quantum dots, and integrated circuits.

According to the review, these potential breakthroughs in graphene biomedical technology over the next few decades could significantly impact several areas of neurosurgery, including neuro-oncology, neurointensive care, neuroregeneration research, peripheral nerve surgery, functional neurosurgery, and spine surgery. The review also provides an introduction to the main properties of graphene and discusses future perspectives of ongoing frontline investigations of graphene, with special emphasis on research fields that are expected to substantially impact experimental and clinical neurosurgery. The topic review was published in the May 2014 issue of Neurosurgery.

“While graphene has been shown to be biocompatible, more basic research is needed to examine the long-term biological effects of graphene implants and to answer other important clinical questions,” concluded study authors Tobias Mattei, MD, and Azeem Rehman, BSc. “Increased awareness of the ongoing frontline research on graphene may enable the neurosurgical community to properly take advantage of the technological applications such a new metamaterial may offer.”

Graphene is a monolayer atomic-scale honeycomb lattice of carbon atoms which combines the greatest mechanical strength ever measured in any material (natural or artificial) with very light weight and high elasticity. Graphene has unique optical and photothermal properties which allow it to release energy in the form of heat in response to light input; it also has very high electrical conductivity. The high surface area allows bioconjugation with common biomolecules. Andre Geim and Kostya Novoselov of the University of Manchester (United Kingdom) were awarded the Nobel Prize in Physics in 2010 for its development.

Related Links:

Invision Health Brain and Spine Center
University of Illinois College of Medicine



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.